SynthesisFrontiers in oncology2025
Hyperthermic intraperitoneal chemotherapy enhances survival outcomes in primary ovarian cancer following cytoreductive surgery: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the therapeutic effect of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with primary ovarian cancer (OC) following cytoreductive surgery (CRS). Methods: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to May 2025. The outcomes were progression-free survival (PFS) and overall survival (OS). Treatment effects were quantified using pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs). Results: This meta-analysis included 10 studies [three randomized controlled trials (RCTs) and seven observational studies] involving 1,668 patients. Patients with primary OC undergoing CRS who received HIPEC treatment in the experimental group demonstrated prolonged PFS (HR = 0.45, 95%CI = 0.29-0.69, Conclusion: HIPEC appears beneficial to the prognosis of patients with primary OC following CRS, particularly after ICS. However, the administration of HIPEC in patients with ECOG 2-3 requires careful clinical consideration. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251036731.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.